Cargando…

NFATC2 is a novel therapeutic target for colorectal cancer stem cells

BACKGROUND: Colorectal cancer stem cells (CRC-SCs) contribute to the initiation and progression of colorectal cancer (CRC). However, the underlying mechanisms for the propagation of CRC-SCs have remained elusive. PURPOSE: The objective of this study was to study the role of NFATC2 in maintenance of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Tingyuan, Ding, Xiaojuan, Kong, Liangsheng, Zhou, Xiaoyan, Zhang, Zhiqi, Ju, Huangxian, Ding, Shijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199214/
https://www.ncbi.nlm.nih.gov/pubmed/30410349
http://dx.doi.org/10.2147/OTT.S169129
_version_ 1783365094823952384
author Lang, Tingyuan
Ding, Xiaojuan
Kong, Liangsheng
Zhou, Xiaoyan
Zhang, Zhiqi
Ju, Huangxian
Ding, Shijia
author_facet Lang, Tingyuan
Ding, Xiaojuan
Kong, Liangsheng
Zhou, Xiaoyan
Zhang, Zhiqi
Ju, Huangxian
Ding, Shijia
author_sort Lang, Tingyuan
collection PubMed
description BACKGROUND: Colorectal cancer stem cells (CRC-SCs) contribute to the initiation and progression of colorectal cancer (CRC). However, the underlying mechanisms for the propagation of CRC-SCs have remained elusive. PURPOSE: The objective of this study was to study the role of NFATC2 in maintenance of the stemness in CRC-SCs. METHOD: The expression levels of mRNA and protein were determined by qRT-PCR and western-blot, respectively. CRC-SCs were isolated by spheroid formation assay and flowcytometry. The sphere-forming and self-renewal abilities of CRC-SCs were determined by spheroid formation assay. The tumorigenicity of CRC-SCs was determined by cell-derived xenograft model. Gene manipulation was performed by lentivirus-mediated delivery system. RESULTS: We first found that NFATC2 is upregulated in primary CRC-SCs. Overexpression of NFATC2 promotes self-renewal and the expression of stem cell markers of CRC-SCs. Conversely, knockdown of NFATC2 attenuates stem cell-like properties of CRC-SCs. Mechanistic analysis indicated that NFATC2 upregulates the expression of AJUBA, downregulates the phosphorylation level of YAP, and therefore activates the transcriptional activities of YAP and promotes the stemness of CRC-SCs. CONCLUSION: Our findings demonstrate NFATC2 as an oncogene that can promote the stemness of CRC-SCs. This work suggests a novel therapeutic strategy against CRC caused by aberrant expression of NFATC2.
format Online
Article
Text
id pubmed-6199214
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61992142018-11-08 NFATC2 is a novel therapeutic target for colorectal cancer stem cells Lang, Tingyuan Ding, Xiaojuan Kong, Liangsheng Zhou, Xiaoyan Zhang, Zhiqi Ju, Huangxian Ding, Shijia Onco Targets Ther Original Research BACKGROUND: Colorectal cancer stem cells (CRC-SCs) contribute to the initiation and progression of colorectal cancer (CRC). However, the underlying mechanisms for the propagation of CRC-SCs have remained elusive. PURPOSE: The objective of this study was to study the role of NFATC2 in maintenance of the stemness in CRC-SCs. METHOD: The expression levels of mRNA and protein were determined by qRT-PCR and western-blot, respectively. CRC-SCs were isolated by spheroid formation assay and flowcytometry. The sphere-forming and self-renewal abilities of CRC-SCs were determined by spheroid formation assay. The tumorigenicity of CRC-SCs was determined by cell-derived xenograft model. Gene manipulation was performed by lentivirus-mediated delivery system. RESULTS: We first found that NFATC2 is upregulated in primary CRC-SCs. Overexpression of NFATC2 promotes self-renewal and the expression of stem cell markers of CRC-SCs. Conversely, knockdown of NFATC2 attenuates stem cell-like properties of CRC-SCs. Mechanistic analysis indicated that NFATC2 upregulates the expression of AJUBA, downregulates the phosphorylation level of YAP, and therefore activates the transcriptional activities of YAP and promotes the stemness of CRC-SCs. CONCLUSION: Our findings demonstrate NFATC2 as an oncogene that can promote the stemness of CRC-SCs. This work suggests a novel therapeutic strategy against CRC caused by aberrant expression of NFATC2. Dove Medical Press 2018-10-15 /pmc/articles/PMC6199214/ /pubmed/30410349 http://dx.doi.org/10.2147/OTT.S169129 Text en © 2018 Lang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Lang, Tingyuan
Ding, Xiaojuan
Kong, Liangsheng
Zhou, Xiaoyan
Zhang, Zhiqi
Ju, Huangxian
Ding, Shijia
NFATC2 is a novel therapeutic target for colorectal cancer stem cells
title NFATC2 is a novel therapeutic target for colorectal cancer stem cells
title_full NFATC2 is a novel therapeutic target for colorectal cancer stem cells
title_fullStr NFATC2 is a novel therapeutic target for colorectal cancer stem cells
title_full_unstemmed NFATC2 is a novel therapeutic target for colorectal cancer stem cells
title_short NFATC2 is a novel therapeutic target for colorectal cancer stem cells
title_sort nfatc2 is a novel therapeutic target for colorectal cancer stem cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199214/
https://www.ncbi.nlm.nih.gov/pubmed/30410349
http://dx.doi.org/10.2147/OTT.S169129
work_keys_str_mv AT langtingyuan nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells
AT dingxiaojuan nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells
AT kongliangsheng nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells
AT zhouxiaoyan nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells
AT zhangzhiqi nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells
AT juhuangxian nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells
AT dingshijia nfatc2isanoveltherapeutictargetforcolorectalcancerstemcells